Lupin Ltd said today that its Investigational New Drug Application (INDA) for the prophylactic treatment of migraine has been approved by the IND Sub-committee of the Indian Council of Medical Research (ICMR); the Sub-committee is headed by the ICMR Director General. ‘Lupin is among a handful of Indian companies to get an INDA approval. The approval is a testimony to Lupin’s world-class R&D. It marks a significant step in Lupin’s long-term strategy towards becoming a research-driven global pharmaceuticals company,’ Lupin Chairman Dr Desh Bandhu Gupta said. Lupin plans to initiate Phase 1 clinical trials in India. A Phase 1 clinical trial is a study for drug safety in humans.